C&R Research Inc.

KOSDAQ listed



Korea's First & The Largest CRO



Drug Development Consulting



Best Certified CRO In Korea



Global Standard Phase I Study Including Caucasian & Asian Patients



The Top Total Value Chain CRO with One-stop Network Solution



E-Clinical Solution

CsafeR

CsafeR PV DB & Safety Reporting Management



imtrial Automatic Clinical Trial Solution Using MDR & CDISC



Best Operating solutions for Innovative clinical Management

Family Site



C&R Academy

System

Academy for Comprehensive Clinical Education



C&R Healthcare Global

Healthcare Acceleration Platform for ASEAN Business Expansion



Site Management Organization for CRC Out-sourcing



Global Clinical Central Lab



Trial Informatics & TI Image


Imaging IT Solution & Imaging CR



ABC BioScience

Early Drug Development Platform

C&R Project Experience







120 +Hypertension & Hyperlipidemia



80 +Cell Therapy



74+ Diabetes Melitus



59+





38 + Botulinum Toxin



25+





9+ CAR-T & CAR-NK




Contact Us

Tel: +82-2-6251-1500 Fax: +82-2-6251-1504 E-mail: BD@cnrres.com



C&R RESEARCH







01 C&R Research Overview

02 Full Service CRO

03 Global CRO

04 Beyond a CRO

05 C&R Team Introduction



C&R Overview

	N	1	1	_	 	 	 	_	 	Δ	h	ΩI	ıt	C	2	R	F	?	29	:6	12	ır	C	h	1
V	ч	, ,									U	V	at.	V	C				CO		, C	ш	U		ı

02 Organization

03 Strong Presence In Global Market

04 Optimization Solutions

05 Early phase clinical trials for global

About C&R Research

Company Name — C&R Research

Foundation Year — 1997.07.01

Headquarter Seoul, South Korea

CEO Moon Tae Yoon

Offices Global: Singapore, Beijing


Korea: Gangnam (Seoul), Busan

Workforce 500+



Organization











Team of Experienced Industry Leaders





CTO







Byung Jin Ahn Executive Vice President

- Medical Advisory Board member, C&R Research
- Assistant Professor, Dongguk University
- M.D., Ph.D., Catholic University of Korea

Sook Jung Jo **Executive Director**

· Director in Biostatistics.

ICON Clinical Research

- · Biometrics Manager, ChongKunDang Pharm. Corp
- Ph.D in Statistics, Korea University

Yong Joo Jung Medical Advisor

- Clinical Examiner, MFDS (9 years)
- · M.D., M.S. in Pharmacy, Master of Medicine (Mmed) in Clinical Pharmacology, Seoul National University

Hyun Chul Baek

Medical Advisor

- Medical Advisor, C&R research
- · M.D. College of Medicine, Korea University
- · Master of Medicine, College of Medicine, Ulsan University (Neurosurgeon)

Yunjeong Choi

Quality Management, Director

- · Clinical Trial Manager, PAREXEL Korea
- Clinical Trial Manager, Hanmi Pharmaceutical
- Ph.D in Pharmacy M.S. in Pharmacy, Seoul National University

Advisory Board

C&R Research also has a global-level advisory board composed of eminent industry leaders across the world including medical professors, statisticians, and pharmaceutical experts. The board allows C&R Research to execute tasks in a closely-connected relationship with university hospitals' Principle Investigators (PIs) and medical staffs.

Korea's No.1 CRO to Globally Competitive CRO



No.1 in Service Revenue

- The fastest growing CRO, CAGR 12.7%
- ONE out of FOUR approved new drugs in Korea is developed by C&R Research
- No.1 CRO in clinical research for registration(IND/NDA) studies in Korea



Worldwide Network

- Branches in China, Singapore
- Partnerships with ACROSS GLOBAL
- Partnership in U.S., Australia, Europe, Thailand, Philippines, India



Korea's First CRO

- 26 years of experience
- Over 1,700 projects and highly customized solutions
- Well-Established network with hospitals in Korea, allowing convenient and efficient site selection and patient enrollment



Best Certified CRO In Korea

Highest Score in 2020 KoNECT CRO Certification Evaluation




Total Value Chain CRO

- End-to-end solution from drug discovery to commercialization
- Comprehensive service scope in line with global standard and best practice supported by integrated services and global partnerships



Strong Presence in Korea, Embedded Global Competitiveness





C&R Research's Partnerships with Korea's Major Hospitals

































*Approximately 35% of Korea's clinical trials take place at the top 5 hospitals in Korea, also known as the "Big 5"

C&R Research's Partnerships with Renowned BioHealth















C&R Research in Action





Full Service CRO

C&R Research provides comprehensive therapeutic & development cycle coverage



Global CRO

C&R Research has an integrated range of worldwide network, which enhances its clinical trial expertise and extends the scope of services beyond expectation



Beyond a CRO

C&R Research is a total value chain CRO that provides end-toend services that exceed the scope of a conventional CRO








Scientific report writing

Service Offerings for Global Trials






© 2023 C&R Research All Rights Reserved I 11

Study Experience






Experience by Therapeutic Area	(2010~2023.1Q)
Oncology	14.8%
Cardiovascular	10.9%
Others	9.6%
Endocrinology	8.5%
Dermatology	7.8%
Nervous System	7.3%
Gastroenterology	5.5%
Musculoskeletal	4.9%
Respiratory	4.8%
Ophthalmology	4.6%
Hepatology	3.2%
Infectious disease	2.3%
Immunology	2.1%
Urology	1.9%
Pain Killer	1.6%
Diagnostics	1.4%
Vaccine	1.4%
Psychiatry	1.2%
Antibiotics	1.0%
Obstetrics and gynecology	1.0%
Rheumatology	1.0%
Surgery	0.8%
Healthy Volunteers	0.7%
ENT	0.6%
Dental	0.4%
Hereditary	0.3%
Medical Device	0.3%


Oncology Study Experience






Experiences by Phase





2010-2023.1Q , Total: 769 studies



2010-2023.1Q , Total: 599 studies

Optimization Solutions: Quality Management Systems



Highly-Advanced Internal Audit Process


- C&R Research has an independent QA team to ensure high quality clinical service.
- Internal audit is conducted under an annual quality assurance plan(QAP)



Therapeutic Area In Proj	ect Audit (2015~2022)
Antibiotics	1
Anesthesiology	1
Cardiovascular	15
Dermatology	9
Diagnostics	1
Endocrinology/Metabolism	3
ENT (Ear,Nose,Throat)	4
Gastro-intestinal	6
Hepatobilliary(Pancreas)	0
Immunology	1
Infectious disease	2
Medical Device	2
Musculoskeletal	0
Nephrology	0
Neurology	7
Obstetrics and gynecology	1
Oncology	13
Ophthalmology	2
Orthopedics	2
Osteoporosis	0
Pain Killer	2
Respiratory	8
Rheumatology	1
Urology	1
Vaccines	1
Others	18
TOTAL	98

Optimization Solutions: In-house data Monitoring







- Helps in efficient SDV performance during on-site monitoring
- Early stage data review
- Investigator/site staff to reduce the noncompliance
- Fix errors of protocol (CRF, DVS, CCG)
- Reduce the number of queries during data cleaning



- Data routine review to identify on inconsistent data, missing data and potential protocol deviations
- Investigator/site staff to reduce the noncompliance
- Finding confirmation of essential documents that can be checked after real data collection



- Enables data to be collected consistently
- Checks for unusual distribution of data
- Intensive targeted monitoring in risk sites Improved
- Cross-functional collaboration of DM (Data Management) part and CDM (Clinical Data Management) part.

Optimization Solutions: Quality Management Systems



Well-Organized SOP Systems based on Local / Global Guidelines

The steps make the following high-quality services available

Ffficient clinical trial

Maintenance of integrity and consistency of clinical service

Helping personnel understand all applicable regulation & minimizing deviation from the requirements

Clearly defining responsibilities of the personnel

OPM (Operating Manual) **WI** (Work Instruction) **Internal Guides or Others** SOP (Standard Operating Procedure) (Supporting Documents) **Company Policy**


Hierarchy of C&R Research Written Procedures

by Priority for Systematic Management

© 2023 C&R Research All Rights Reserved | 17

Optimization Solutions: Data Driven Clinical Trial








Beyond a CRO



Total Value Chain CRO





Integrated Services





C&R Healthcare Global is a leading healthcare business platform that guides clients to effectively execute their business strategy throughout the entire drug development process from incubation to commercialization. Located in Singapore, C&R Healthcare Global sets a solid foundation for bio/health companies to make a successful transition from local/regional to global entities.

C&R Academy is a clinical training institute that has been officially designated by the Ministry of Food and Drug Safety (MFDS). By providing global-level, systematic education programs for CRAs, C&R Academy enhances their contributions to the clinical sector. C&R Academy has grown its expertise in clinical training beyond the perimeter of C&R Research, providing education for CRAs of all affiliation.



C&R Academy

RESEARCH RESEARCH

C&R Academy

MFDS Designated CRA Training Institute

				The same		1795		Strategic or the Assessment					
분류	Course	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	ОСТ	NOV	DEC
신규	Fundamental of Clinical Research (5Days)			2~6	6~10	18~22	1~5	13~17	24~28		12~16	9~13	
	Clinical Research of Medical Device (1Day)										20		
신규 심화 보수	GCP Training (1Day)	21					16		20				2
	Non-Interventional Study (1Day)						11					4	
	Basic Course of Clinical Research (3Days)							22~24		23~25		24~26	
	CPM_Fundamental (2Days)					27,28							
	CPM_Advanced (2Days)										6.7		•
	DM/STAT (1Day)			24								19	
	Drug Development (1Day)			21				8					
	Early Phase Study (1Day)			1						2			
시회 비스	Monitoring Practice (2Days)				13,14			12,13					8,9
심화 보수	Medical Writing in Clinical Research (2Days)				25,26							17,18	
	Oncology Clinical Trial (2Days)					17,18					22,23		
	Pharmacovigilance (1Day)			14						9			
	Quality Assurance (1Day)				21						29		
	Regulatory Affairs in Clinical Research (1Day)		24								27		
	Risk-based Quality Management (2Days)		26,27										16,17
	Study Start up Training (1Day)	22						19					

C&R Academy 기초/심화

On/Off-line Training

GCP Training Management System

Curriculum & Schedule


https://lms.cnracademy.org



© 2023 C&R Research All Rights Reserved | 22

C&R Research Partners & Collaborative Services










C&R Research has an integrated range of worldwide network, which enhances its clinical trial expertise and extends the scope of services beyond expectation

01 Global Services and Coverage

02 Global Presence

EARLY PHASE CLINICAL TRIALS FOR GLOBAL





Present & Future



Timeline



People



Budget



Partnership & Commitment

2020~

- 한국에서도 다양한 인종으로 임상 진행 가능
- •미국대비 50%~60% 수준의 임상 진행 비용
- 식약처 사전 상담을 통한 빠른 임상 진행 및 준비 및 부족한 부분의 보완
- FDA PRE-IND 미팅을 고려한 미국에서의 데이터 인정
- MFDS, EMA 동시 진행을 통한 추가 대상자 등록 방안 및 데이터 통용성 확보
- CDISC 적용을 통한 글로벌 수준의 데이터 완성
- •실제 한국에서 1,2 상 진행하고 해당 데이터를 인정 받는 CASE

Ideal strategy on clinical trial considering country specific requirements



		FDA (US)	PMDA (Japan)	NMPA(China)	EMA (EU)	MFDS (Korea)
IND	СТД	2018년 05월 의무화		2021년 9월 의무화	IMPD 의무화 * CTD: Module 3,4,5 * IMPD: CTD Module 2	
IND	CDISC	2017년 12월 의무화				
NDA	СТД	2017년 05월 의무화	2020년 4월 의무화	2021년 9월 의무화	2010년 1월 의무화 국가별로 비 eCTD를 허용하는 국가도 있음	2009년 3월 의무화 (신약 only) 2023년10월 전문의약품 의무화 예정
	CDISC	2016년 12월 의무화	2020년 4월 의무화	2019년 9월 권고		

IND

미국 및 중국을 제외한 대부분의 국가는 CTD 제출 필요 없음 / CDISC는 미국만 제출 필요

NDA

대부분의 국가에서 CTD 제출 필요 / CDISC는 미국 및 일본만 제출 필요

Global Services and Coverage

RESEARCH RESEARCH

0016 0000 16	Clabal Chudy Evpaniones (22 Chudis	
/11110~/11/5 11	I GIONAL SILINV EXNERIENCE / 3 SILINIE	
	Global Study Experience : 23 Studie	



				TESETATE
Year	Sponsor	Indication	Phase	Scope
2016	Company B	Oncology	2	PRT RA CO PV
2016	Company D	Oncology	2/3	PRT CO PV DM STAT CSR
2017	Company D	Oncology	2	DM STAT
2018	Company B	Oncology	Others	RA
2018	Company G	Nervous System	1/2	DM STAT CSR
2018	Company D	Oncology	PMS	PRT
2019	Company S	Oncology	1	PRT CO PV DM STAT CSR Others
2019	Company P	Oncology	1	CO
2019	Company R	Others	Others	PRT
2019	Company R	Others	Others	Others
2020	Company Y	Antibiotics	Others	RA
2020	Company G	Infectious disease	1/2	PRT
2021	Company D	Oncology	3	DM STAT
2021	Company Y	Others	Others	RA
2021	Company G	Infectious disease	2	CO PV DM
2022	Company E	Dermatology	1	RA CO PV DM STAT
2022	Company I	Musculoskeletal	2	PRT
2022	Company I	Musculoskeletal	1	DM STAT CSR
2022	Company F	Hepatology	2	RA CO PV
2022	Company T	Hepatology	2	RA
2022	Company R	nAMD	3	PRT RA CO PV DM STAT CSR
2023	Company C	Gastroenterology	2	RA
2023	Company Q	Oncology	1/2	CO

| C&R Thailand.



MOU with CMU

Chiang Mai University와 MOU를 체결


Local Office

- A Dr. Prapan. Director of C&R Chiang Mai
- B 1 CRA 계약 for Feasibility



Global Presence





One Team - Study Management Technologies & Tools



